Clinical trialHuman
The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin
Clinical endocrinology, 1999 Jan. Rahim A, O'Neill PA, Shalet SM.
Study type
Clinical trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Clinical endocrinology
Published
1999 Jan
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Administration, CutaneousAgedAged, 80 and overBiomarkersDrug Administration ScheduleFemaleHumansMaleOligopeptidesPituitary-Adrenal SystemProlactinTime Factors
Other papers on Hexarelin
Randomized controlled trial · 1999
Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans
Clinical trial · 2001Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy
Review · 2014The cardiovascular action of hexarelin
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page